Chromosome 21 rearrangement in acute biphenotypic leukemia

C Theodossiou; A Scalise; L Silverman; V Najfeld

doi:10.1016/0165-4608(92)90323-z

Chromosome 21 rearrangement in acute biphenotypic leukemia

Cancer Genet Cytogenet. 1992 Nov;64(1):56-9. doi: 10.1016/0165-4608(92)90323-z.

Authors

C Theodossiou¹, A Scalise, L Silverman, V Najfeld

Affiliation

¹ Tumor Cytogenetics Laboratory, Poly Annenberg Levy Hematology Center, Mount Sinai School of Medicine, New York.

PMID: 1360869
DOI: 10.1016/0165-4608(92)90323-z

Abstract

A patient with myelodysplastic syndrome (MDS) and a 47,XY,+21 karyotype at diagnosis, was documented to have a clonal chromosome 21 rearrangement, i(21q), four months before transformation to acute biphenotypic leukemia. For 4 months after transformation, isochromosome 21 persisted while the patient was receiving treatment with zidovudine. Vitamin D3 was added to zidovudine for an additional month, during which time the trisomy 21 clone reappeared as the predominant cell population. The unique aspects of this patient are the atypical evolution of chromosome 21, the transformation to biphenotypic leukemia, and the occurrence of i(21q) associated with biphenotypic leukemia evolving from an MDS.

MeSH terms

Anemia, Refractory, with Excess of Blasts / complications
Anemia, Refractory, with Excess of Blasts / drug therapy
Anemia, Refractory, with Excess of Blasts / genetics
Antigens, CD / analysis
Antigens, Differentiation, Myelomonocytic / analysis
CD13 Antigens
Cell Transformation, Neoplastic
Cholecalciferol / therapeutic use
Chromosomes, Human, Pair 21*
Gene Expression Regulation, Leukemic
Gene Rearrangement*
Humans
Immunophenotyping
Leukemia, Myeloid, Acute / etiology
Leukemia, Myeloid, Acute / genetics*
Receptors, Interleukin-2 / analysis
Trisomy*
Zidovudine / therapeutic use

Substances

Antigens, CD
Antigens, Differentiation, Myelomonocytic
Receptors, Interleukin-2
Cholecalciferol
Zidovudine
CD13 Antigens